This article is more than 5 years old. Information may no longer be current.
Xen reduces both IOP and medication use in refractory glaucoma
Click Here to Manage Email Alerts
CORONADO, Calif. — In a group of refractory glaucoma patients, the ab interno placement of Allergan’s Xen45 gel stent reduced both IOP and medication use at 12 months, Davinder S. Grover, MD, MPH, and colleagues reported in a poster presented at the American Glaucoma Society meeting.
Of 65 patients implanted with the gel stent, 76.3% achieved a 20% or greater reduction in IOP from baseline, and 69.2% of patients needed fewer medications. At baseline, 84.6% of patients were using more than three hypotensive medications; the mean number of medications decreased from 3.5 at baseline to 1.7 at month 12.
Nine patients were considered nonresponders and required secondary surgical intervention. Twenty-one patients required needling; of these, 18 had no complications, one had transient hypotony, and two had worsening as seen on biomicroscopy. Ten of the 21 patients achieved more than 20% reduction in IOP from baseline on the same or fewer medications.
No patients needed more medications, and no intraoperative complications were reported.
Patients were included if they had prior failure of a filtering or cilioablative procedure or uncontrolled IOP on maximum medication, and if medicated IOP and mean diurnal IOP was between 20 mm Hg and 35 mm Hg. – by Patricia Nale, ELS
Reference:
Grover DS. Multicenter, single-arm, open-label study of the intraocular pressure-lowering effect and complications of an ab interno implanted gelatin stent in refractory glaucoma: 12-month results. Poster presented at: American Glaucoma Society annual meeting; March 2-5, 2017; Coronado, Calif.
Disclosure: Grover reports he is a consultant and speaker for Allergan and Reichert Technologies. Allergan sponsored the study.